Pharmacology: kinetics/dynamics + some drugs Flashcards
Enzyme kinetics
- 3 types and their axes and their shapes
- Michaelis-Menten: Velocity vs. [Substrate] - hyperbole
- Lineweaver-Burk: 1/V vs. 1/[S] - linear
- Enzyme inhibition: 1/V vs. 1/[S] - linear
Km and affinity
inversely related to affinity of enzyme for substrate
Vmax and enzyme concentration
Vmax directly proportional to enzyme concentration
sigmoid curve indicative of what?
cooperative kinetics, like Hb
Kinds of enzyme inhibitors (3)
reversible competitive
irreversible competitive
noncompetitive
which ones bind to active sites
the competitive ones
how does Vmax change with inhibitors
unchanged with reversible competitive
you need less enzyme for irreversible and noncompetitive inhibition b/c less substrates to act at
how does Km change with inhibitors
increased with reversible competitive b/c that’s how reversible compt acts, by being more affinitive for substrate
unchanged for irreversible and noncompetitive inhibition
how does pharmacodynamics change with inhibitors
reversible: decreased potency
irreversible: decreased efficacy
noncompetitive: decreased efficacy
Pharmacokinetics: what is it
what the body does with drugs
absorb, distribute, metabolize, excrete
Pharmacodynamics: what is it
how the body is affected by drugs
Bioavailability
- IV
- PO
fraction of unchanged drug in systemic circulation
- IV: 100%
- PO: < 100% 2/2 incomplete absorption and first-pass metabolism
Vd (volume of distribution)
amount of drug in body / plasma drug concentration
where is it low Vd
medium Vd
high Vd?
low: blood
medium: ECF
high: all tissues, including fat
half life
t = (0.693 x Vd) / CL
how many half-lives does it take at costant infusion to ready steady state
4-5
Clearance (CL)
- what is it
- equation
- what can affect it
- volume of plasma cleared of drug per unit time
- CL = Vd x Ke (elimination constant)
- CL = (rate of elimination) / (plasma drug concentration)
- renal, hepatic, or cardiac f(x)
Loading dose calculation
(Cp x Vd) / F
Cp = target plasma concentration at steady state F= dosing frequency
Maintenance dose calculation
(Cp x CL x tau) / F
tau = dosage interval
Time to reach steady state dependent on?
only half life
independent of dose and dosing frequency
zero-order elimination
constant amount of drug eliminated per time
examples of zero-order elimination meds
Phenytoin
Ethanol
ASA
PEA is round, like 0
first-order elimination
rate directly proportional to drug present
constant proportion of drug eliminated per time
exponential curve
what is each elimination process “limited/dependent on?
zero-order is capacity limited
first-order s flow-dependent
urine clears ionized or neutral forms
ionized
neutral ones reabsorbed
weak acids
- trapped where?
- examples
- treat overdose with?
- basic environments
- Phenobarbital, MTX, ASA
- bicarbonate to pull off the proton from the toxin and make it ionic so it stays in urine for excretion
weak bases
- trapped where
- examples
- treat overdose with?
- acidic environments
- amphetamines
- ammonium chloride to add proton to base and make it ionic so it stays in urine for excretion
phase I drug metabolism
- steps
- who loses it
- what does it yield
- Reduction
- Oxidation
- ## Hydrolysiswith Cyt P-450
- geriatrics lose phase I
- usu yields slightly polar, water-soluble metabolites (often still active)
phase II drug metabolism
- steps
- what does it yield
- Conjugation:
1. Glucoronidation
2. Acetylation
3. Sulfation - usu yields very polar, inactive metabolites that are renally excreted
- geriatrics still have this phase of drug metabolism
efficacy vs. potency
- efficacy: maximal EFFECT a drug can produce
- potency: AMOUNT needed for given effect
high efficacy drugs classes (4)
- analgesia meds
- abx
- anti-histamine
- decongestant
highly potent drug classes (3)
- chemo
- anti-htn
- lipid-lowering
reversible competitive antagonist for Diazepam
- which receptor
flumazenil on GABA rec
noncomp antagonist for glutamate
- which receptor
ketamine on NMDA rec
irreversible competitive antag for NE
- which receptor
phenoxybenzamine on alpha-receptors
partial agonist for morphine
- which receptor
buprenorphine on opioid mew-rec
which affects potency and which affects efficacy
- reversible competitive antagonists affect potency b/c you can overcome the competition by adding more substrate
- irreversible competitive antagonists and noncompetitive antagonists affect efficacy b/c no matter how much more you put in, you can’t get the same effect
Therapeutic index equation
safer drugs have higher or lower TI?
TD50 / ED 50
TD50 = median toxic dose ED50 = median effective dose
safer drugs have higher TI b/c greater difference b/w toxic and effective dose
examples of low TI drugs
digoxin
lithium
theophylline
warfarin
parasympathetic NS
- pre-/post-ganglionic NTs and the receptors
- exceptions
- what cells are targets
- Pre releases Ach onto nAchR of post
- Post releases Ach onto mAchR of targets
- no exceptions
- cardiac muscle, smooth muscle, glands, nerve terminals
sympathetic NS
- pre/postG NTs and receptors
- exceptions
- what cells are targets
- Pre releases Ach onto nAchR of post
- Post releases NE to alpha and betas
UNLESS - Post releases D to D1 recetors
- Post release Ach to mAchR at sweat glands
- Adrenal medulla receives only Ach onto nAchR from preG and itself releases Epi, NE
- NE targets: cardiac muscle, smooth muscle, glands, nerve terminals
- D targets: renal vasculature, smooth muscle
botulinum blocks what
release of Ach at all terminals
how many muscarinic AchRs?
5, M1-5
examples of GPCR’s (13)
- adrenergics: alpha-1 and 2 + beta-1 and 2
- muscarinics: M1-3
- Dopamine: D1 and 2
- Histamine: H1 and 2
- Vasopressin: V1 and 2
alpha-1 = which GPCR
Gq
alpha-2 = which GPCR
Gi
beta-1 = which GPCR
Gs
beta-2 = which GPCR
Gs
M1 = which GPCR
Gq
M2 = which GPCR
Gi
M3 = which GPCR
Gq
D1 = which GPCR
Gs
D2 = which GPCR
Gi
H1 = which GPCR
Gq
H2 = which GPCR
Gs
V1 = which GPCR
Gq
V2 = which GPCR
Gs
summary of GPCR from adrenergic, muscarinic, dopa, hista, vaso
QISS, QIQ, SI, QS, QS
kiss quick, yes, ks, ks
Gq’s
alpha-1, M1, M3, H1, V1
Gs’s
beta-1, beta-2, D1, H2, V2
Gi’s
alpha-2, M2, D2
actions of alpha-1
- vascular smooth muscle contraction
- pupillary dilator muscle contraction (mydriasis)
- intestinal and bladder sphincted muscle
Gq, so muscle contractions
actions of alpha-2
- decreased sympathetic outflow
- decreased insulin release
- decrease lipolysis
- decreased blood flow (increased plt aggregation)
Gi, so decreases stuff
actions of beta-1
- increased HR
- increased contractility
- increased renin
- increased lipolysis
Gs, so increases stuff
actions of beta-2
- increases blood flow (vascodilation)
- increases breathing (bronchodilation)
- increases HR
- increases contractility
- increases lipolysis
- increases insulin release
- increases aqueous humor production
- ciliary muscle relaxation - impedes aqueous humor flow … creates pressure in eye for functioning?
- decrease uterine tone … don’t want to be delivering in fight-flight situation
Gs, so increases stuff beta-2, so increases more stuff than beta-1
actions of M1
CNS and enteric NS
Gq
actions of M2
decrease HR and atria contractility
Gi, so decreases stuff
actions of M3
- increase exocrine gland secretions w/muscle contractions
- increase gut peristalsis w/muscle contractions
- increase bladder muscle contraction
- increase bronchomuscle contraction (bronchoconstriction)
- increase pupillary sphincter muscle contraction (miosis)
- increases ciliary muscle contraction (accomodation and allows flow of aqueous humor)
Gq, so muscle contractions
actions of D1
relaxes renal vascular smooth muscle
actions of D2
modulates NT release, esp in brain
actions of H1
- increase nasal and bronchial mucus production
- increase vascular permeatbility
- contraction of bronchioles
- pruritus
- pain
actions of H2
- increases gastric acid secretion by parietal cells
actions of V1
- increase vascular smooth muscle contraction
Gq, so muscle contraction
actions of V2
- increase water permeability and reabsorption in collecting tubules
Gs, so increases stuff (2 b/c 2 kidneys)
What happens to NE once it gets into the synaptic space (3) things
- diffusion, metabolism
- immediate reuptake via transporter
- negative feedback by action on pre-syn alpha-2
choline transporter inhibitor
Hemicholinium
Ach vesicule loading inhibitor
Ves.ami.col
Ach release inhibitor
botulinum
Tyrosine hydroxylase inhibitor
Metyrosine
Dopamine vesicle loading inhibitor
Reserpine
vesciular NE release inhibitor
Bretylium
Guanethidine
vesicular NE release stimulator
amphetamines
NE reuptake inhibitor
coke, TCA, amphetamines
Cholinomimetic agents (4)
Bethanechol
Cabachol
Pilocarpine
Metacholine